Stem Cell Therapeutic and Research Reauthorization Act of 2025

Plain-English Summary: Stem Cell Therapeutic and Research Reauthorization Act of 2025

This bill reauthorizes — meaning it renews and continues — a federal program related to stem cell therapies and research. Based on its title and history, this legislation is a continuation of previous laws (passed in 2005, 2010, and 2015) that established and maintained the National Cord Blood Inventory and related stem cell transplant programs. These programs support the collection, storage, and use of cord blood (blood from umbilical cords after birth) and bone marrow donations, which can be used to treat serious diseases like leukemia, sickle cell disease, and other blood disorders.

The bill primarily affects patients who need stem cell or bone marrow transplants, medical researchers working on related treatments, hospitals and transplant centers, and the organizations that maintain national registries of donors and stored cord blood units. By reauthorizing these programs, the federal government would continue funding efforts to expand the supply of diverse donor matches — which is especially important for patients from racial and ethnic minority backgrounds, who often have a harder time finding compatible donors.

Without reauthorization, these programs could lose their legal authority and federal funding, potentially disrupting the supply of life-saving transplant materials. The bill has been referred to the House Committee on Energy and Commerce, where it will be reviewed before any further action. This type of reauthorization bill is generally considered routine maintenance of existing health programs.